Pacira Biosciences, INC Form 4 insider transactions

Pacira BioSciences Director Samit Hirawat was granted 6,405 restricted stock units and 10,891 stock options on June 10, 2026.

Senior Vice President of Finance Lauren Riker sold 6,115 shares of Pacira BioSciences common stock via a 10b5-1 plan.

Pacira BioSciences director Christopher Christie was granted 6,405 restricted stock units and 10,891 stock options.

Director Thomas G. Wiggans was granted 32,675 stock options in Pacira BioSciences, Inc. as part of standard compensation.

Director Alethia Young received a grant of restricted stock units and stock options as part of standard compensation.

Pacira BioSciences director Michael J. Yang was granted 6,405 restricted stock units and 10,891 stock options.

Director Marcelo Bigal received a grant of 6,405 restricted stock units and 10,891 stock options.

Director Mark Froimson received a grant of restricted stock units and stock options as part of annual compensation.

Director Laura Brege received a grant of 6,405 restricted stock units and 10,891 stock options as part of annual compensation.

Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, Inc., reported the withholding of 3,187 shares to cover tax obligations.

Chief Medical Officer Jonathan Slonin disposed of 4,728 shares of Pacira BioSciences to satisfy tax withholding obligations.

Chief Administrative Officer Kristen Williams sold 10,259 shares of Pacira BioSciences following a tax-related share withholding.

Pacira BioSciences CFO Shawn Cross exercised options and sold 12,941 shares under a pre-established Rule 10b5-1 trading plan.

Pacira BioSciences CFO Shawn Cross exercised and sold 12,059 shares of common stock under a pre-established 10b5-1 trading plan.

Pacira BioSciences, Inc. filed an amended Form 4 to correct the number of restricted stock units granted to Director Mark A. Kronenfeld.

Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, filed a Form 4 indicating a future sale of 3,261 shares of common stock on March 17, 2026, under a pre-arranged 10b5-1 trading plan.

Pacira BioSciences, Inc. Director Mark Froimson sold 500 shares of the company's common stock at $21.81 per share.

Pacira BioSciences, Inc. Chief Financial Officer Shawn Cross was granted 49,091 restricted stock units, vesting annually starting February 2027.

Pacira BioSciences, Inc. Chief Administrative Officer Kristen Williams was granted 54,546 restricted stock units as part of her compensation.

Pacira BioSciences' Chief Commercial Officer, Brendan Teehan, was granted 51,714 restricted stock units, vesting over four years.

Pacira BioSciences, Inc. Senior Vice President of Finance, Lauren Riker, was granted 19,273 restricted stock units, vesting over four years.

Pacira BioSciences' Senior VP of Finance, Lauren Riker, reported the sale of 4,000 shares under a 10b5-1 plan and the withholding of 2,751 shares for tax obligations.

Pacira BioSciences' Chief Administrative Officer, Kristen Williams, reported the sale of company common stock, including shares withheld for tax obligations and shares sold under a 10b5-1 plan.

Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, disposed of 6,168 shares of common stock to cover tax withholding obligations.

Pacira BioSciences' Chief Commercial Officer, Brendan Teehan, disposed of 5,182 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Pacira BioSciences CEO Frank D. Lee disposed of 41,488 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Pacira BioSciences, Inc. director Samit Hirawat was granted 39,291 stock options with an exercise price of $19.85, vesting over three years.

Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, reported the disposition of 381 common shares to cover tax withholding obligations related to a restricted stock unit award.

Pacira BioSciences' Senior Vice President of Finance, Lauren Riker, reported a sale of common stock and shares withheld for tax obligations.

Pacira BioSciences CEO Frank D. Lee reported a disposition of 9,272 shares of common stock to cover tax obligations related to a restricted stock unit award.